Trial Profile

A Phase I proof-of-concept clinical trial of ALE-F02 in advanced liver and kidney fibrosis

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lixudebart (Primary)
Indications Hepatic fibrosis; Pulmonary fibrosis; Renal fibrosis
Focus First in man; Proof of concept; Therapeutic Use

Most Recent Events

26 Apr 2023 Positive topline results from multiple-ascending dose cohorts presented in an Alentis Therapeutics Media Release.
13 Apr 2023 According to an Alentis Therapeutics media release, multiple ascending dose Phase 1 study completion is about to happen.
09 Jan 2023 Results published in the Alentis Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com